Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Dysbiosis of the Gut Microbiota01:18

Dysbiosis of the Gut Microbiota

The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical Septal Myectomy and Atrial Myxoma Resection: Two Diseases, One Heart, and a Case Report.

The American journal of case reports·2026
Same author

Metabolomic signatures prior to in-hospital cardiac arrest: insights into potential therapeutic targets.

Scientific reports·2026
Same author

Septic Cardiac Remodeling: A New Concept in Cardiac Dysfunction Induced by Experimental Sepsis.

Antioxidants (Basel, Switzerland)·2026
Same author

Effects of Early Treatment with Lipid Core Nanoparticles-Associated Methotrexate on Cardiac Remodeling and Soleus Muscle Inflammasomes in Infarcted Rats.

International journal of molecular sciences·2026
Same author

A Developmental Perspective on the Intestinal Microbiota in Crohn's Disease.

International journal of molecular sciences·2026
Same author

Varietal Differences in Kidney Beans Modulate Gut Microbiota and Inflammation During High-Fat Diet-Induced Obesity in Male Mice.

Nutrients·2026
Same journal

Nonlinear Redox-Immune Coupling Under Low-Dose-Rate Radiation: A Compartment-Specific Framework for Biological Responses-A Narrative Review.

Antioxidants (Basel, Switzerland)·2026
Same journal

Clonal Hematopoiesis and Gut Microbiota-Derived TMAO as Candidate Amplifiers of Cardiovascular Inflammation: The CHIDT Hypothesis.

Antioxidants (Basel, Switzerland)·2026
Same journal

A Mitochondria-Targeted Nitroxide Radical Mitigates Radiation-Induced Liver Injury by Attenuating Oxidative Stress and Preserving Mitochondrial Function.

Antioxidants (Basel, Switzerland)·2026
Same journal

Alternol-Induced Oxidative Modification of SQSTM1/p62 Is Associated with Nrf2 Signaling and Autophagy-Related Responses in Prostate Cancer Cells.

Antioxidants (Basel, Switzerland)·2026
Same journal

The Global Decline in Sperm Count and Testosterone Levels: Trends, Mechanisms, and Environmental Drivers.

Antioxidants (Basel, Switzerland)·2026
Same journal

Reactive Oxygen and Nitrogen Species in Plants-2nd Edition.

Antioxidants (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

Liraglutide Modifies Gut Microbiota Without Modulating Doxorubicin-Induced Toxicity in Rats.

Carolina R Tonon1, Marina G Monte1, Paola S Ballin1

  • 1Internal Medicine Department, Botucatu Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil.

Antioxidants (Basel, Switzerland)
|May 27, 2026
PubMed
Summary
This summary is machine-generated.

This study found that doxorubicin causes gut damage and alters gut bacteria in rats. Liraglutide, a GLP-1 analog, did not prevent this toxicity, despite changing the gut microbiome.

Keywords:
GLP-1doxorubicingut microbiotaintestinal toxicityshort-chain fatty acids

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Related Experiment Videos

Last Updated: May 28, 2026

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Microbiology

Background:

  • Doxorubicin (chemotherapy) causes significant gastrointestinal toxicity, impacting treatment effectiveness and patient well-being.
  • Glucagon-like peptide-1 (GLP-1) analogs, like liraglutide, are explored for potential therapeutic benefits.
  • Understanding doxorubicin's gut effects and potential mitigation strategies is crucial for cancer therapy.

Purpose of the Study:

  • To investigate the impact of liraglutide on acute doxorubicin-induced gastrointestinal toxicity in a rat model.
  • To assess changes in colon structure, fecal short-chain fatty acids, and gut microbiota composition.
  • To determine if liraglutide can attenuate doxorubicin's adverse effects on the gut.

Main Methods:

  • Sixty male Wistar rats were divided into four groups: Control, Doxorubicin, Liraglutide, and Doxorubicin + Liraglutide.
  • Liraglutide was administered subcutaneously for two weeks; doxorubicin was given as a single intraperitoneal dose.
  • Colon tissue, feces, and blood were collected 48 hours post-doxorubicin administration for analysis.

Main Results:

  • Doxorubicin induced colon crypt damage, goblet cell loss, apoptosis, and reduced fecal short-chain fatty acids.
  • Gut microbiota analysis revealed altered beta-diversity, with a decrease in Bacteroidetes and an increase in Proteobacteria post-doxorubicin.
  • Liraglutide alone altered microbial profiles but did not mitigate doxorubicin-induced structural damage or SCFA reduction.

Conclusions:

  • Acute doxorubicin administration causes significant intestinal structural damage, reduces beneficial short-chain fatty acids, and dysregulates gut microbiota composition.
  • While liraglutide influences the gut microbiome, it does not provide a protective effect against acute doxorubicin-induced gut toxicity in this model.
  • Further research is needed to explore alternative strategies for managing chemotherapy-induced gastrointestinal toxicity.